Kiwi germ killer Zoono moved ahead 18 per cent in early trade after telling investors it expects to report a maiden full-year profit.

Zoono makes anti-microbial sprays designed to disinfect surfaces, kill mould — and even treat acne.

Its product range is based around the “Zoono Molecule: a unique, antimicrobial molecule that bonds to any surface and kills pathogens including bacteria, viruses, algae, fungi and mould.”

Today the business told investors it expected $NZ3.4 million revenue compared to about $NZ839,000 last year — a jump of more than 300 per cent.

“The group has also made an unaudited maiden profit for the year,” Zoono told investors.

June quarter cash was $NZ487,000 — up from $NZ190,000 in the previous quarter.

But the business still reported cash-burn of about $2 million for the year including spending of $411,000 in the June quarter.

That was partly because of “higher product manufacturing and operating costs for the quarter … a result of a shipment to Korea and higher associated costs”.

Sales in China were also “slower-than-expected” prompting Zoono to look for aditional sales options beyond its local sales represenative “including selling direct cross border into China”.

Zoono Group shares (ASX:ZNO) over the past year
Zoono Group shares (ASX:ZNO) over the past year